Scientists demonstrate means of reducing Alzheimer's-like plaques in fly brain

July 16, 2008

But overexpression of Neprilysin causes other serious pathologies

Neuroscientists at Cold Spring Harbor Laboratory (CSHL) are part of a collaboration that has succeeded in demonstrating that overexpression of an enzyme in the brain can reduce telltale deposits causally linked with Alzheimer's disease.

CSHL Professor Yi Zhong, Ph.D., whose lab studies genetic mechanisms involved in neurodegenerative illnesses, helped develop a line of transgenic fruit flies that was central in the experiments. Transgenic organisms express genes that occur naturally in other species. In this instance, the fruit flies were engineered to express a human gene that codes for the production of an enzyme called neprilysin, or NEP.

Beta amyloid and the pathology of Alzheimer's

NEP enzymes are known from prior experiments to degrade protein deposits in the brain that are characteristic of Alzheimer's . The protein clumps -- sheet-like plaques between brain cells called beta amyloid deposits -- have been found in the autopsied brains of human Alzheimer's patients.

Two types of beta amyloid sheets are associated with Alzheimer's plaques. Scientists have suspected that so-called Aβ42 plaques -- those structurally composed of 42-amino acid beta amyloid peptides -- are involved in the genesis of the illness. "But the mechanism by which Aβ42 reaches pathological levels in the brains of late-onset patients is not well understood," Dr. Zhong explained.

Past experiments in transgenic mice expressing human beta amyloid had shown that a deficiency of NEP caused a series of serious problems. The deficiency accelerated the formation of amyloid plaques, caused dysfunction in the synapses, or gaps, across which nerve cells in the brain communicate, and caused memory defects.

Reversing the process: mixed results

In new experiments, Dr. Zhong and other team members, who include Kanae Iijima-Ando, Ph.D., of the Farber Institute for Neurosciences and neuroscientists from Thomas Jefferson University in Philadelphia, sought to turn the tables. If NEP deficiency caused pathology, what would happen if NEP enzymes were expressed in above-normal amounts in brain cells affected by beta amyloid plaques?

Using transgenic fruit flies, the team found that by overexpressing human NEP in fly neurons, accumulation of Aβ42 inside the neurons was reduced. The scientists also observed that outright death of neurons due to Aβ42 plaques was suppressed.

At the same time, the experiment produced results that were not at all encouraging. Although NEP overexpression fought off plaques, chronic overexpression in the fly brain caused age-related degeneration of the axons that connect nerve cells, and also shortened the lifespan of the flies. The team believes that this effect was caused by the unintended impact of chronic NEP activity upon a critical gene-regulating protein, a transcription factor called CREB.

The team wants to test whether the life-shortening impact of NEP overexpression upon CREB occurs in transgenic mammals -- for instance, in mice, which are genetically closer to humans than flies.

"We have succeeded in demonstrating both protective and detrimental aspects of high NEP activity in the fly brain," Dr. Zhong said. "We also noted a reduction of NEP activity in fly brains that correlates with age. These are intriguing clues about mechanisms that contribute to the causation of Alzheimer's.

"We must now seek additional knowledge about the physiological mechanisms that underlie age-dependent downregulation of NEP in flies. This is a powerful genetic model system that we hope will lead us to discover novel therapeutics to combat Alzheimer's, a disease that devastates so many people every year."

Cold Spring Harbor Laboratory

Emerging Drugs and Targets for Alzheimer's Disease: Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism (RSC Drug Discovery)
by Ana Martinez (Editor), David E Thurston (Editor)

Alzheimer's disease is the most prevalent neurodegenerative disorder in the elderly. A recent study from the Bloomberg School of Public Health recently estimated that over 26 million people were living with the disease in 2006 and that the global prevalence of the disease will grow to 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the disease's progression were made, it could have a huge impact on global public health. According to this study, interventions that could delay the onset of the disease by as little as one year would reduce the prevalence of the disease by 12 million fewer cases in 2050. These figures reinforce how...

Amyloid Proteins
by Jean D. Sipe (Editor)

A first-stop reference on proteins associated with amyloidosis.
This book is the first to present a systematic overview of all known fibril-forming proteins, including their biochemical characteristics and pathophysiology. It considers the clinically recognized amyloid proteins that are known to be associated with the amyloid protein folding disorders, dealing with their common structural and thermodynamic features that lead to amyloid fibril formation and disease. Emphasis is on the thermodynamics of protein folding, the structure and physiologic effects of common oligomeric and subfibrillar intermediates and the influence of the extracellular matrix and cellular trafficking and metabolism on the genesis and catabolism of beta pleated sheet proteins.
The chapters on specific...

Amyloid, Prions, and Other Protein Aggregates, Part B, Volume 412 (Methods in Enzymology)
by Ronald Wetzel (Editor), Indu Kheterpal (Editor)

The ability of polypeptides to form alternatively folded, polymeric structures such as amyloids and related aggregates is being increasingly recognized as a major new frontier in protein research. This new volume of Methods in Enzymology along with Part C (volume 413) on Amyloid, Prions and other Protein Aggregates continue in the tradition of the first volume (309) in containing detailed protocols and methodological insights, provided by leaders in the field, into the latest methods for investigating the structures, mechanisms of formation, and biological activities of this important class of protein assemblies.

* Presents detailed protocols
* Includes troubleshooting tips
* Provides coverage on structural biology, computational...

Amyloid, Prions, and Other Protein Aggregates, Part C, Volume 413 (Methods in Enzymology)
by Ronald Wetzel (Editor), Indu Kheterpal (Editor)

The ability of polypeptides to form alternatively folded, polymeric structures such as amyloids and related aggregates is being increasingly recognized as a major new frontier in protein research. This new volume of Methods in Enzymology along with Part B (volume 412) on Amyloid, Prions and other Protein Aggregates continue in the tradition of the first volume (309) in containing detailed protocols and methodological insights, provided by leaders in the field, into the latest methods for investigating the structures, mechanisms of formation, and biological activities of this important class of protein assemblies.

* Presents detailed protocols
* Includes troubleshooting tips
* Provides coverage on structural biology, computational...

Amyloid Precursor Protein: A Practical Approach
by Weiming Xia (Editor), Huaxi Xu (Editor)

In the search for an effective treatment for Alzheimer's disease, APP is a unique model protein that illustrates the wide array of basic and sophisticated characterization techniques available.

Exploring a variety of biological techniques to clarify the structure and function of this transmembrane protein, this text presents each method with detailed, step-by-step protocols to achieve reproducible results and provide a framework for studying other membrane proteins.

Amyloid-beta: Webster's Timeline History, 1988 - 2007
by Icon Group International (Author)

Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Amyloid-beta," including when used in literature (e.g. all authors that might have Amyloid-beta in their name). As such, this book represents the largest compilation of timeline events associated with Amyloid-beta when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social...

Amyloid Beta: Webster's Timeline History, 1987 - 2007
by Icon Group International (Author)

Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Amyloid Beta," including when used in literature (e.g. all authors that might have Amyloid Beta in their name). As such, this book represents the largest compilation of timeline events associated with Amyloid Beta when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social...

Alzheimer's Disease: Cellular and Molecular Aspects of Amyloid beta (Subcellular Biochemistry)
by Robin Harris (Editor), Falk Fahrenholz (Editor)

This book contains a survey of present-day research into the biomedical fundamentals of Alzheimer’s disease (AD). It contains 20 chapters dealing with widely ranging topics, all of which have a bearing upon the understanding and treatment of AD. Starting with a broad survey of the contribution that the various microscopical techniques (light microscopy, electron microscopy, atomic force microscopy) have made since the seminal light microscopical studies of Alois Alzheimer, the book presents chapters on specialist topics: transgenic mouse models of AD; the enzymology of amyloid-ß production and degradation; oxidant stress and antioxidant protection; the involvement of metal ions and the influence of chelators; the importance of amyloid-ß oligomers and fibrils, the role of cholesterol...

The Structure and Function of Alzheimer's Amyloid Beta Proteins (Medical Intelligence Unit)
by David Schubert (Editor)

Fibrous Proteins: Amyloids, Prions and Beta Proteins, Volume 73 (Advances in Protein Chemistry)
by John M. Squire (Author), David A.D. Parry (Author), Andrey Kajava (Author)

Amyloids, Prions and Beta Proteins is the last volume of the three-part thematic series on Fibrous Proteins in the Advances in Protein Chemistry serial. Fibrous proteins act as molecular scaffolds in cells providing the supporting structures of our skeletons, bones, tendons, cartilage, and skin. They define the mechanical properties of our internal hollow organs such as the intestines, heart, and blood vessels. This volume covers such topics as Beta-Structures in Fibrous Proteins; B-Silks: Enhancing and Controlling Aggregation; Beta-Rolls, Beta-Helices and Other Beta-Solenoid Proteins; Natural Triple B-Stranded Fibrous Folds; Structure, Function and Amyloidogenesis of Fungal Prions: Filament Polymorphism and Prion Variants; X-Ray Fiber and powder Diffraction of PRP Prion Peptides; From...